Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 3 2Phase 2 1Phase 1 1

Status

Completed 3Unknown 2Terminated 1

Sponsor Class

OTHER 20INDUSTRY 6OTHER_GOV 2

Study Type

Interventional 6

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Pain 4Neoplasms 2Cancer Pain 1

Interventions

pembrolizumab 1019Carboplatin 959Paclitaxel 932Gemcitabine 793Cisplatin 748Docetaxel 682Bevacizumab 610Pemetrexed 502Nivolumab 486Cyclophosphamide 466Capecitabine 461Fluorouracil 417Dexamethasone 402Rituximab 372Oxaliplatin 347Injections 342atezolizumab 297Trastuzumab 297Leucovorin 286Cetuximab 282Irinotecan 266130-nm albumin-bound paclitaxel 252Prednisone 244Doxorubicin 240Ipilimumab 226Lenalidomide 220Fulvestrant 217fludarabine 214durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × Hydromorphone × Clear all
NCT03564548 2021-07-28

REBORN

Tetra Bio-Pharma

Phase 2 Unknown
20 enrolled
Tumor-Agnostic

Neoplasms

NCT01824524 2014-08-15

A Pharmacokinetic and Safety Study of Osmotic Release Oral System (OROS) Hydromorphone in Non-Opioid Tolerant Chinese Participants With Cancer

Xian-Janssen Pharmaceutical Ltd.

Phase 1 Completed
12 enrolled

Pain

NCT01205126 2014-02-03

An Efficacy and Safety Study of Oral Osmotic Therapeutic System (OROS) Hydromorphone Hydrochloride (HCl) in Participants With Cancer Related Pain

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3 Completed
260 enrolled 12 charts

Pain

NCT00766831 2013-10-23

An Efficacy and Safety Study of Hydromorphone Oral Osmotic System (OROS) in Korean Participants With Cancer Pain

Janssen Korea, Ltd., Korea

Phase 4 Completed
190 enrolled 17 charts

Cancer Pain

NCT01648699 2013-10-11

Safety and Efficacy Study of Osmotic Release Oral System (OROS) Hydromorphone in Participants With Cancer Pain

Janssen Pharmaceutica

Phase 4 Terminated
20 enrolled 9 charts

Neoplasms, Pain

NCT00822614 2009-01-14

FINDS

Akela Pharma, Inc.

Phase 3 Unknown
500 enrolled

Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡